Monoclonal antibodies (mAbs) can block the PD-1/PD-L1 inhibitory pathway, reactivate the recognition and cytotoxicity of immune cells, and avoid the immune escape of tumor cells [19,20]. The gene discussed is PDCD1; the disease is neoplasm.